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Albizzia lebbeck Benth. (Mimosaceae) is a medicinal tree used to treat several inﬂammatory ailments in
the Indian traditional Ayurvedic system of medicine. The aim of the present study was to evaluate the
possible anti-inﬂammatory activity of the aqueous (AE) and ethanolic (EE) extracts of the leaves
of A. lebbeck to support the ethnopharmacological claims. The study was carried out using Wistar rats
(100e150 g). The AE and EE were prepared using the Soxhlet extraction process. The anti-inﬂammatory
activity of the AE and EE of the leaves of A. lebbeck were studied using carrageenan-induced paw edema
and cotton pellet-induced granuloma models. The AE and EE of the leaves of A. lebbeck at doses of 50,
100, and 200 mg/kg p.o. (oral administration) showed a dose-dependent and signiﬁcant (p < 0.05)
inhibition of carrageenan-induced hind paw edema with maximum percentage inhibition (PI) values of
22.34, 30.85, 39.36 and 22.53, 32.98, 42.55, respectively. The AE and EE at doses of 50, 100, 200 mg/kg
p.o. signiﬁcantly (p < 0.05) inhibited granuloma formation with PI values of 19.07, 27.57, 38.55 and 23.93,
32.23, 42.33, respectively. The AE and EE of the leaves of A. lebbeck showed signiﬁcant (p < 0.05) anti-
inﬂammatory activity.
Copyright © 2014, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. All rights reserved.1. Introduction
Understanding inﬂammation has always been an enigma for
mankind. Something as minor as a bruise or something as major as
a myocardial infarction can trigger this phenomenon. The major
classes of drugs to suppress inﬂammation are nonsteroidal anti-
inﬂammatory agents (NSAIDS) and corticosteroids but their toxic
adverse effects such as epigastric distress, peptic ulceration, oste-
oporosis, and iatrogenic Cushing's syndrome have limited their
use.1,2 Looking at the present scenario, medicinal compounds
derived from plant sources such as ﬂavonoids, saponins, alkaloids,ology, 6th ﬂoor, Vardhman
nner Ring Road, New Delhi,
hram).
for Food and Biomolecules,
molecules, National Taiwan Univeterpenoids, glycosides, and coumarins could provide an excellent
fountainhead to develop new anti-inﬂammatory agents, which
could be more efﬁcacious, safer, affordable, and accessible for
patients.
Albizzia lebbeck Benth. (Mimosaceae), commonly known as
‘Sirisa’ in Sanskrit, is a tall, unarmed, deciduous tree distributed
throughout India. The traditional systems of medicine have been
utilizing various parts of the tree to treat several inﬂammatory
ailments such as asthma, bronchitis, arthritis, allergies, snake bites,
fractures, hemicranias, gingivitis, toothaches, and sinusitis.3,4 It is
also claimed that the tree is useful in night blindness, cataract,
leukoderma, erysipelas, leprosy, tuberculosis, scabies, amoebiasis,
syphilis, spermatorrhoea, and piles.5,6
The bark of A. lebbeck has stolen the limelight by its pleotropic
activities such as anti-inﬂammatory, immunomodulatory, anal-
gesic, antiarthritic, antioxidant, antimalarial, antitumor, and anti-
fertility activities, pushing the leaves to the background.7e17
Despite the leaves being the most abundant and accessible me-
dicinal part of the tree, possessing anticonvulsive, nootropic,
antimicrobial, and antiulcer activities, there are no studiesrsity. Production and hosting by Elsevier Taiwan LLC. All rights reserved.
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phytochemical analysis of the leaves has revealed the presence of
potentially bioactive alkaloids, triterpenoid saponins, and tri-O-
glycoside ﬂavonoids.22e24 This study was hence undertaken to
evaluate the possible anti-inﬂammatory activity of aqueous (AE)
and ethanolic (EE) extracts of the leaves of A. lebbeck in rats at
different doses.2. Materials and methods
2.1. Plant material
The leaves were obtained from the botanical garden of the Ali-
garh Muslim University (AMU), Aligarh in May 2011 and were
authenticated by Dr Wazahat Hussain, a taxonomist, and a voucher
specimen (voucher no. 2149) was deposited in the Department of
Botany, AMU for further reference. The shade-dried leaves were
ground homogenously using a mixer-grinder and approximately
100 g of the powder subjected to Soxhlet extraction, for 16 hours
using 5 L of distilled water and 5 L of 99.9% ethanol (Scientiﬁc OEM,
Mumbai, India) as solvents. The dark green, semi-solid extracts
obtained were made free from the solvents by placing them in an
incubator at 60C for 12 hours. The yield of the AE was 21% and that
of the EA was 12.398%. Previous toxicity studies of the leaves of
A. lebbeck did not show any toxicity and behavioral changes in rats
up to 2000 mg/kg p.o. (oral administration) dose,21 hence doses of
50, 100, and 200 mg/kg p.o. were selected for the present study.2.2. Animals
Wistar rats (100e150 g) were obtained from the Animal House,
Jawaharlal Nehru Medical College (JNMC), Aligarh. They were
housed at a temperature of 24 ± 2C, 12-hour light/dark cycles,
35e60% humidity, in polypropylene cages, and fed a standard ro-
dent diet with water ad libitum. Animals were deprived of food but
not water 4 hours before the experiment.2.3. Drugs
Indomethacin (Merck, Bangalore, India), Diclofenac (Reckitt
Benckiser, Gurgaon, India), and Carrageenan (Sigma Chemicals, St.
Louis, MO, USA) were procured from the respective companies and
were used in the study.2.4. Ethical considerations
Experimental procedures and protocols used in this study were
approved by the Institutional Animal Ethics committee of the JNMC
and conform to the “Guidelines for care and use of animals in sci-
entiﬁc research” (Indian National Science Academy 1998, Revised
2000).2.5. Carrageenan-induced rat paw edema model
The rats were divided into eight groups (n ¼ 6), each receiving
distilled water (control), diclofenac 20 mg/kg p.o. (reference stan-
dard), and 50, 100, 200 mg/kg p.o. dose of the AE and EE of
A. lebbeck, respectively. Carrageenan (0.1 mL of 1%) was injected
into the subplantar tissue of the right hind-paw of each rat. The
volume of the carrageenan injected into the foot wasmeasured at 0,
30, 60, 120, and 180 minutes using a plethysmometer (Biodevices,
New Delhi, India). The percentage inhibition (PI) at each time in-
terval was calculated25:PI ¼ ðVt  V0Þ control ðVt  V0Þ treatedðVt  V0Þ control
 100
V0 ¼ Mean paw volume at 0 hours
Vt ¼ Mean paw volume at a particular time interval
2.6. Cotton pellet-induced granuloma model
The rats were divided into eight groups (n ¼ 6), each receiving
distilled water (control), indomethacin 10 mg/kg p.o. (reference
standard), and 50, 100, 200 mg/kg p.o. dose of the AE and EE of
A. lebbeck, respectively. Thirty minutes after drug administration,
an autoclaved cotton pellet of 10 ± 1.0 mg was aseptically
implanted subcutaneously in the back region of the rats while
anesthetized with ether (Scientiﬁc OEM, Mumbai, India). Extracts
were administered once daily for the next 7 days. On Day 8, animals
were anesthetized again and cotton pellets (Datt Mediproducts
Ltd., New Delhi, India) were removed surgically, freed from the
extraneous tissue, and dried in a hot-air oven overnight at 60C.
The dried pellets were weighed and the increment in the dry
weight of the pellets was taken as a measure of granuloma for-
mation. The PI of granuloma tissue development was calculated26:
PI ¼Weight of pellet ðcontrolÞ weight of pellet ðtestÞ
Weight of pellet ðcontrolÞ  100
2.7. Estimation of median effective dose
The median effective dose (ED50) values were estimated using
GraphPad Prism software version 5.03 (GraphPad Software Inc., San
Diego, CA, USA). The PI values obtained from the carrageenan-
induced paw edema and cotton pellet-induced granuloma models
were initially normalized to percentage activity assuming that the
maximal response (100%) is seen at the dose of 200 mg/kg and the
minimal response (0%) is seen at the dose of 0 mg/kg of the AE and
EE. The logedose response curves were then generated using a
normalized nonlinear regression curve model, and by interpolation
of the log dose (best-ﬁt value) 50% activity was obtained. The
antilog of the obtained log dose produced the ED50 value.
2.8. Statistical analysis
Results were expressed as mean ± standard error of the mean
(SEM). Statistical analysis was performed using one-way analysis of
variance (ANOVA) followed bymultiple Tukey's comparison tests. A
p value < 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Carrageenan-induced paw edema model
The AE and EE of the leaves of A. lebbeck (50, 100, 200 mg/kg,
p.o.) showed a dose-dependent, signiﬁcant inhibition of
carrageenan-induced rat paw edema from 0.5 hours to 3 hours
following drug administration, compared to the control group. The
maximum PI of paw edema by the AE was observed as 22.34
(p < 0.05), 30.85 (p < 0.05), and 39.36 (p < 0.05) at the doses of 50,
100, 200 mg/kg p.o., respectively. The maximum PI of paw edema
by the EE was observed as 25.53 (p < 0.05), 32.98 (p < 0.05), and
42.55 (p < 0.05) at the doses of 50,100, 200mg/kg p.o., respectively.
Diclofenac 20 mg/kg p.o. showed a maximum PI of 61.70% at 3
hours after its administration (Table 1). The ED50 values of the AE
and the EE were 28.91 mg/kg and 27.23 mg/kg, respectively.
Table 1
Effect of the AE and EE of the leaves of Albizzia lebbeck with carrageenan-induced paw edema in rats.
Paw volume (mL)
Groups Before 0 h 1/2 h 1 h 2 h 3 h
Distilled water 0.97 ± 0.03 1.03 ± 0.03 1.67 ± 0.07 1.97 ± 0.06 2.02 ± 0.07 1.97 ± 0.04
Diclofenac 20 mg/kg 1.00 ± 0.04 1.07 ± 0.06 1.48 ± 0.03* (35.94) 1.63 ± 0.03* (40.23) 1.58 ± 0.02* (48.48) 1.43 ± 0.03* (61.70)
AE 50 mg/kg 0.97 ± 0.04 1.07 ± 0.04 1.60 ± 0.03 (17.19) 1.83 ± 0.03 (19.15) 1.85 ± 0.02* (21.21) 1.80 ± 0.03* (22.34)
AE 100 mg/kg 0.95 ± 0.03 1.02 ± 0.03 1.52 ± 0.03 (21.88) 1.73 ± 0.02* (24.47) 1.75 ± 0.02* (26.26) 1.67 ± 0.02* (30.85)
AE 200 mg/kg 0.92 ± 0.03 0.98 ± 0.04 1.45 ± 0.02* (26.56) 1.63 ± 0.03* (30.85) 1.65 ± 0.04* (32.32) 1.55 ± 0.03* (39.36)
EE 50 mg/kg 0.95 ± 0.03 1.07 ± 0.03 1.60 ± 0.03 (17.19) 1.81 ± 0.03* (21.27) 1.83 ± 0.02* (23.23) 1.77 ± 0.03* (25.53)
EE 100 mg/kg 1.00 ± 0.03 1.07 ± 0.04 1.57 ± 0.03 (21.88) 1.77 ± 0.05* (25.53) 1.78 ± 0.03* (28.28) 1.70 ± 0.03* (32.98)
EE 200 mg/kg 0.98 ± 0.03 1.08 ± 0.01 1.53 ± 0.01 (29.69) 1.72 ± 0.02* (32.21) 1.73 ± 0.02* (34.34) 1.62 ± 0.03* (42.55)
Values are presented as the mean ± SEM, n ¼ 6 in each group; values given in parentheses represent PI.
One-way ANOVA followed by multiple Tukey's comparison test.
*p < 0.05, as compared to the control group.
AE ¼ aqueous extract of the leaves of A. lebbeck; ANOVA ¼ analysis of variance; EE ¼ ethanolic extract of the leaves of A. lebbeck; PI ¼ percentage inhibition; SEM ¼ standard
error of the mean.
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The AE and EE showed a signiﬁcant (p < 0.05) inhibition of the
granuloma weight at all the doses. The PI of the granuloma weight
by the AE was 19.07, 27.57, and 38.55 at the doses of 50, 100,
200 mg/kg p.o., respectively. The PI of the granulomaweight by the
EE was 23.93, 32.23, and 42.33 at the doses of 50, 100, and 200 mg/
kg p.o., respectively. Indomethacin 10 mg/kg p.o. showed the
highest PI of 60.76 (p < 0.05). The anti-inﬂammatory action was
dose-dependent for both the AE and EE (Table 2). The ED50 values of
the AE and EE were 37.56 mg/kg and 30.17 mg/kg, respectively.
4. Discussion
In this study, we evaluated the anti-inﬂammatory activity of the
AE and EE of the leaves of A. lebbeck by two experimental models,
i.e., carrageenan-induced paw edema and cotton pellet-induced
granuloma model. The carrageenan-induced paw edema model is
used to screen the anti-inﬂammatory activity of a drug in the acute
phase of inﬂammation. Edema induced by carrageenan is believed
to be biphasic.27,28 The ﬁrst phase (1 hour) involves the release of
serotonin and histamine and the second phase (> 1 hour) is
mediated by cyclooxygenase products. Continuity between the two
phases is provided by kinin.29 The AE and EE of the leaves of
A. lebbeck signiﬁcantly inhibited the edema formation in both the
ﬁrst and second phases. The anti-edematous activity of A. lebbeck in
the ﬁrst phase could be due to the possible suppression of hista-
mine signaling by the mast cell stabilizing effect,10,30,31 and direct
inhibition of histamine H1 receptor and histidine decarboxylase
gene transcriptions.32 Another possible explanation could be theTable 2
Effect of the AE and EE of the leaves of Albizzia lebbeckwith the cottonpellet-induced
granuloma model in rats.
Groups Dry weight of cotton pellet (mg) PI
Distilled water 51.07 ± 3.57236
Indomethacin 10 mg/kg 20.04 ± 0.88921* 60.76
AE 50 mg/kg 41.33 ± 2.53243* 19.07
AE 100 mg/kg 36.99 ± 0.86422* 27.57
AE 200 mg/kg 31.38 ± 1.02288* 38.55
EE 50 mg/kg 38.85 ± 1.42238* 23.93
EE 100 mg/kg 34.61 ± 0.54223* 32.23
EE 200 mg/kg 29.45 ± 0.47099* 42.33
Values are presented as the mean ± SEM, n ¼ 6 in each group.
One-way ANOVA followed by multiple Tukey's comparison test.
*p < 0.05, as compared to the control group.
AE ¼ aqueous extract of the leaves of A. lebbeck; ANOVA ¼ analysis of variance;
EE ¼ ethanolic extract of the leaves of A. lebbeck; PI ¼ percentage inhibition;
SEM ¼ standard error of the mean.corticotrophic action of A. lebbeck as evidenced by a raise in plasma
cortisol levels,33 which antagonizes nuclear factor-kappa-B (NF-
kB).34 In the present study, the anti-edematous activity of the AE
and EE persisted in the second phase with the maximal effect
observed at 3 hours. This could be explained by the possible inhi-
bition of the release and/or action of kinin and prostaglandin by
A. lebbeck.8
The cotton pellet-induced granuloma method is a well-known
model to screen the anti-inﬂammatory activity in the chronic
phase of inﬂammation,35 which is characterized by monocyte
inﬁltration, ﬁbroblast proliferation, angiogenesis, and exudation.36
The dry weight of the cotton pellet correlates well with the amount
of granulomatous tissue formed.37 In this study, the AE and EE
decreased the dry weight of the granuloma signiﬁcantly when
compared to the control groups. This may be due to the ability of
A. lebbeck in reducing the number of ﬁbroblasts, preventing
angiogenesis and synthesis of collagen and mucopolysaccharide.9
The suppression of the T helper 1 (Th-1) T-lymphocyte pathway,
which releases inﬂammatory cytokines such as interleukin-12 and
interferon-g, may also be responsible for this action.38 However,
mechanistic studies measuring speciﬁc cytokine levels may help
elucidate this reasoning.
A previous study evaluating the anti-inﬂammatory activity of
the bark of A. lebbeck showed a maximum PI of 58.94 and 53.57 for
the EE in the carrageenan-induced paw edema and cotton pellet
granulomamodels, respectively.9 In the present study, the EE of the
leaves showed a maximum PI of 42.55 and 42.33 in the respective
models. Hence, it is suggested that the anti-inﬂammatory activity of
the bark is higher than that of the leaves.
The preliminary phytochemical analysis of the leaves of
A. lebbeck shows the presence of several compounds such as alka-
loids, steroids, terpenoids, tannins, glycosides, ﬂavonoids, and sa-
ponins.39 The high performance thin layer chromatography (HPTLC)
proﬁle studies on the petroleumether extract revealed the presence
of 10 different alkaloids with retention factor (Rf) values between
0.02 and 0.85. The ethyl acetate extract displayed the presence of
ﬁve different alkaloids with Rf values between 0.09 and 0.84. The
methanolic extract disclosed the presence of four different alkaloids
with Rf values ranging from0.02 to 0.79.22 Each of these 19 alkaloids
is yet to be characterized. Two-dimensional paper chromatography
studies on the hydroethanolic extract of the leaves disclosed
the presence of two tri-O-glycoside ﬂavonols, i.e., kaempferol 3-O-
a rhamnopyranosyl(1/6)-b-glucopyranosyl(1/6)-o-galactopyr-
anoside and quercetin 3-O-a rhamnopyranosyl(1/6)-b-
glucopyranosyl(1/6)-b-galactopyranoside. Their structures were
elucidated by electrospray ionization mass spectrometry (ESI-MS)
and 1H and 13C nuclear magnetic resonance (NMR) spectral anal-
ysis.24 The n-butanolic fraction of the methanolic extract of leaves




copyranosyloleanolate). Its structurewas characterized byNMRand
fast atom bombardment mass spectroscopy (FABMS).23
It is difﬁcult to attribute the observed effects of the leaves of
A. lebbeck to any one particular chemical moiety. Flavonoids and
saponins are known to exhibit their anti-inﬂammatory effect by
several mechanisms40,41 along with a wide spectrum of other
pharmacological effects such as analgesic, antioxidant, antimicro-
bial, antiviral, anticancer, antidiabetic, and antiplatelet activities.42
Hence, in light of present experimental and HPTLC data available,
the anti-inﬂammatory activity of the leaves of A. lebbeck could be
attributed to its ﬂavonoids and saponins.
5. Conclusion
It can be concluded that the AE and the EE of the leaves of
A. lebbeck possess anti-inﬂammatory activity thus validating the
ethnopharmacological claims. This knowledge could be tapped to
formulate new agents to treat inﬂammatory and allergic ailments.
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